Related Experiment Video
Updated: Sep 30, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
[Effect of diazoxide on severe pulmonary hypertension]
1Hospital Nacional de Rehabilitación Respiratoria María Ferrer, Buenos Aires, Argentina.
Abstract:
Hemodynamic effects were studied after the administration of incremental doses of diazoxide (upper range 300-600 mg) in a group of 15 patients with severe pulmonary hypertension due to different etiologies. No significant changes were found in the mean pulmonary arterial pressure (PAP), "wedge" pressure, right atrial pressure, and right ventricular systolic work index (RVSWI). Significant decreases were found in the mean systemic arterial pressure, pulmonary arterial resistance (PAR), systemic arterial resistance (SAR) and left ventricular systolic work index (LVSWI). Significant increments were found in the cardiac output (Q), heart rate and PAR/SAR ratios (Table 1). A significant correlation was found between Q and SAR pretreatment (r = -0.75, p less than 0.002); PAR and SAR pretreatment (r = 0.69, p less than (0.01); change in SAR vs change in Q produced by diazoxide (r = -0.81, p 0.001); basal PAR/SAR vs D PAP (change pre-post diazoxide) (r = -0.58, p less than 0.05); % PAR/SAR vs % PAP (percent changes in PAR/SAR post diazoxide vs percent change of PAP post diazoxide) (r = 0.78, p less than 0.001); D PAP vs D RVSWI (PAP change post diazoxide vs RVSWI change post diazoxide) r = 0.79, p less than 0.001. No significant correlation (either in absolute or in percent values) was found between basal values of pulmonary artery pressure, cardiac output, pulmonary arterial resistance or right ventricular systolic work index vs those produced by the drug in the same parameters. Patients were divided into two groups according to the decrease or increase of pulmonary arterial pressure after diazoxide administration (n = 7 and 8, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...

